Paclitaxel (PTX) has been demonstrated to be one of the most effective anticancer agents available at present ([Carney, 1996](#bib4){ref-type="other"}; [Khayat *et al*, 2000](#bib22){ref-type="other"}). Besides its antitumour activity, its ability to induce radiosensitisation has been reported both *in vitro* ([Tishler *et al*, 1992](#bib41){ref-type="other"}; [Choy *et al*, 1993](#bib9){ref-type="other"}; [Lokeshwar *et al*, 1995](#bib26){ref-type="other"}; [Rodriguez *et al*, 1995](#bib34){ref-type="other"}) and *in vivo* ([Milas *et al*, 1994](#bib30){ref-type="other"}, [1995](#bib31){ref-type="other"}; [Cividalli *et al*, 1998](#bib11){ref-type="other"}) this effect has been attributed to its effect of stabilising microtubules and inducing cell cycle arrest at the G2/M phase, the most radiosensitive phase of the cell cycle ([Terasima and Tolmach, 1963](#bib40){ref-type="other"}; [Sinclair and Morton, 1966](#bib38){ref-type="other"}). As several clinical studies have demonstrated the efficacy of PTX-based chemotherapy combined with radiotherapy, the combined modality is considered to be a potentially important treatment option for lung and breast cancer ([Choy *et al*, 1998a](#bib7){ref-type="other"}, [1998b](#bib10){ref-type="other"}, [2000](#bib8){ref-type="other"}; [Dowell *et al*, 1999](#bib13){ref-type="other"}; [Formenti *et al*, 2003](#bib16){ref-type="other"}; [Kao *et al*, 2005](#bib21){ref-type="other"}).

The adverse effects of radiation, namely, lung toxicities in patients with breast or lung cancer treated by thoracic radiation, are of great concern, and may be dose limiting or even have a negative impact on the quality of life of the patients, even though radiation is an efficient treatment option. Lung toxicities often result in lung fibrosis, necessitating change of the treatment method and causing much distress or even death of the patients ([Penney and Rubin, 1977](#bib33){ref-type="other"}; [Early Breast Cancer Trialists\' Collaborative Group, 2000](#bib14){ref-type="other"}; [Lind *et al*, 2002](#bib25){ref-type="other"}). Some clinical trials actually reported an increased incidence of pneumonitis following combined PTX therapy with radiation in patients with breast or lung cancer ([Taghian *et al*, 2001](#bib39){ref-type="other"}; [Hanna *et al*, 2002](#bib20){ref-type="other"}; [Chen and Okunieff, 2004](#bib5){ref-type="other"}).

Although widely used, PTX itself has several adverse effects, such as peripheral sensory neuropathy ([Rowinsky *et al*, 1993](#bib35){ref-type="other"}; [Rowinsky and Donehower, 1995](#bib36){ref-type="other"}), and its poor solubility in water is also associated with such effects as anaphylaxis and other severe hypersensitivity reactions attributable to Cremophor EL and ethanol, which are essential for solubilising PTX ([Weiss *et al*, 1990](#bib43){ref-type="other"}; [Rowinsky and Donehower, 1995](#bib36){ref-type="other"}). In order to overcome these problems, we prepared a new formulation, NK105, which is a PTX-incorporating polymeric micellar nanoparticle (85 nm in size) ([Hamaguchi *et al*, 2005](#bib19){ref-type="other"}). NK105 is formed by facilitating the self-association of amphiphilic block copolymers constructed using polyethylene glycol (PEG) as the hydrophilic segment and modified polyaspartate as the hydrophobic segment in an aqueous medium. Owing to the PEG constituting the outer shell of the micelles, NK105 is soluble in water. In addition, PEG also confers a stealth property to the formulation, that allows the micellar drug preparation to be less avidly taken up by the reticuloendothelial system (RES) and to be retained in the circulation for a longer period of time ([Klibanov *et al*, 1990](#bib24){ref-type="other"}, [1991](#bib23){ref-type="other"}; [Allen, 1994](#bib1){ref-type="other"}; [Gabizon *et al*, 1996](#bib18){ref-type="other"}). The prolonged circulation time and the ability of NK105 to extravasate through the leaky tumour vasculature (i.e., the EPR (enhanced permeability and retention) effect) causes accumulation of PTX in tumour tissues ([Matsumura and Maeda, 1986](#bib29){ref-type="other"}; [Maeda and Matsumura, 1989](#bib27){ref-type="other"}). We previously demonstrated that NK105 is associated with reduced neurotoxicity and also exerts more potent antitumour activity on human cancer xenograft, as compared to free PTX. In addition, because of its solubility in water, it is expected that the incidence of anaphylaxis and hypersensitivity reactions attributable to Cremophor EL and ethanol may also be reduced with NK105. A clinical trial of NK105 is now under way.

In this context, it is expected that the use of NK105 in place of PTX in combination with radiation may also yield superior results, because of the more potent antitumour activity of this drug as compared to that of free PTX. In this study, we evaluated the antitumour activity and severity of lung fibrosis induced by PTX and NK105 administered in combination with thoracic radiation, to examine whether combined NK105 chemotherapy with radiation would be an acceptable or useful treatment modality.

MATERIALS AND METHODS
=====================

Mice
----

Eight-week-old female C57BL/6J mice were purchased from Charles River Japan Inc. (Kanagawa, Japan). All the animal procedures were performed in compliance with the guidelines for the care and use of experimental animals, drawn up by the Committee for Animal Experimentation of the National Cancer Center; these guidelines meet the ethical standards required by law and also comply with the guidelines for the use of experimental animals in Japan.

PTX and NK105
-------------

Paclitaxel was purchased from Merican Corp. (Tokyo, Japan). NK105 is a PTX-incorporating 'core-shell-type\' polymeric micellar nanoparticle formulation that was prepared by a previously reported procedure ([Hamaguchi *et al*, 2005](#bib19){ref-type="other"}). Briefly, polymeric micellar particles were formed by facilitating the self-association of amphiphilic block copolymers in an aqueous medium. The polymer of NK105 was constructed using PEG as the hydrophilic segment and modified polyaspartate as the hydrophobic segment. The carboxylic groups of the polyaspartate block were modified by the esterification reaction with 4-phenyl-1-butanol, resulting in conversion of half of the groups to 4-phenyl-1-butanolate. Molecular weight of the polymers was determined to be approximately 2000 (PEG block: 12 000; moditied polyaspartate block: 8000).

Via the self-association process, PTX was incorporated into the inner core of the micelle system by physical entrapment through hydrophobic interactions between the drug and specifically well-designed block copolymers for PTX. NK105 was obtained as a freeze-dried formulation and contained ca.23% (WW^−1^) of PTX. Finally, NK105, PTX-incorporating polymeric micellar nanoparticle formulation with a single and narrow size distribution, was obtained. The weight-average diameter of the nanoparticles was approximately 85 nm ranging from 20 to 430 nm.

Irradiation
-----------

The mice were anesthetised by intraperitoneal (i.p.) injection of nembutal (75 mg kg^−1^) and placed on the stage for irradiation. The whole thorax or subcutaneous (s.c.) tumours of the thigh were irradiated using a Faxitron cabinet X-ray system model CP-160 by 100 kV X-rays from a linear accelerator, at a dose rate of 2 Gy min^−1^. Totally 12 Gy was irradiated to each mouse. The whole body except irradiated parts, lung field or tumour lesion, were shielded with specially designed lead blocks.

Flow cytometry
--------------

At 24 h after the injection of PTX or NK105 into the Lewis lung carcinoma (LLC) tumour-bearing C57BL/6j mice, the tumours were excised, minced in PBS, and fixed in 70% ethanol at 4°C for 48 h. After being fixed, the tumours were digested with 0.04% pepsin (Sigma chemical co., St Louis, MO, USA) in 0.1 [N]{.smallcaps} HCl for 60 min at 37°C in a shaking bath for preparing single-nuclei suspensions. The nuclei were then centrifuged, washed twice with PBS, and stained with 40 *μ*g ml^−1^ of propidium iodide (Molecular Probes, OR, USA) in the presence of 100 *μ*g ml^−1^ RNase in 1 ml PBS for 30 min at 37°C. The stained nuclei were analysed with a B-D FACSCalibur (BD Biosciences, San Jose, CA, USA). The cell cycle distribution was analysed using the Modfit program (Verity Software House Inc., Topsham, ME, USA).

Evaluation of the antitumour activity
-------------------------------------

For this experiment, 3 × 10^6^ LLC cells were inoculated s.c. into the right thighs of mice. The tumour volume was calculated using the formula, tumour volume (mm^3^)=*a* × *b*^2^/2 (*a*=longest tumour diameter, *b*=shortest tumour diameter). When the tumour volume reached approximately 100 mm^3^ on day 14 after the tumour inoculation, the mice were randomly allocated to test groups of about four or five mice each, and started the treatment on the same day. There were six test groups, as follows: untreated control, PTX treatment alone, NK105 treatment alone, radiation alone, combined PTX treatment with radiation, and combined with NK105 treatment with radiation.

In the groups receiving PTX or NK105, the mice were administered a single intravenous (i.v). injection of PTX or NK105 at the dose of 45 mg kg^−1^; 24 h after the drugs were administered, the tumour sites of the mice in the groups scheduled to receive radiation were irradiated.

The antitumour activity of each treatment regimen was evaluated by measuring the tumour volume. Tumour volume and body weight was measured every 3 days.

Evaluation of lung toxicity
---------------------------

The severity of lung toxicity was evaluated histologically in the following test groups; untreated control (*n*=6), radiation treatment alone (*n*=6), combined PTX treatment with radiation (*n*=9), and combined NK105 treatment with radiation (*n*=10). Mice were administered a single i.v. injection of PTX or NK105 at the dose of 45 mg kg^−1^; 24 h after the drugs were administered, the thorax of the mice in the groups scheduled to receive radiation was irradiated. All the mice were killed 36 weeks after the drug administration. At the time of the killing, the lungs were removed, and the right lungs were fixed in 10% buffered formalin for 24 h, then embedded in paraffin. The lungs were inflated at 20 cm water pressure by intratracheal infusion of 10% buffered formalin before fixation. Sections (5 *μ*m- thick) were stained with haematoxylin and eosin (H&E) and observed under the light microscope. The severity of the pulmonary fibrosis was assessed based on Ashcroft\'s scoring system ([Ashcroft *et al*, 1988](#bib3){ref-type="other"}). Briefly, all the fields of each lung section were scanned under a Leica microscope at a magnification of × 100, then each field was visually graded from 0 (normal lung) to 8 (total fibrotic obliteration of the field). The mean grades obtained for all of the fields was then calculated as the visual fibrotic score.

Immunohistochemistry
--------------------

The lung sections were deparaffinised and rehydrated, then microwaved in 0.01 [M]{.smallcaps} sodium citrate buffer for 15 min at 90°C to retrieve epitopes, and cooled at room temperature. An endogenous peroxidase blocking solution of 3% hydrogen peroxide was applied for 20 min at room temperature. After blocking the nonspecific binding sites with 2% normal goat serum, the sections were incubated with rabbit anti-mouse collagen III immunoglobulin G (IgG) (Chemicon International, Temecula, CA, USA) overnight at 4°C. The sections were then washed with PBS, followed by the addition of biotin-conjugated goat anti-rabbit IgG (Vector Laboratories Inc., Burlingame, CA, USA) and incubation for 30 min at room temperature. The sections were then washed and incubated with horseradish-peroxidase-conjugated avidin--biotin complex (Vector Laboratories Inc., Burlingame, CA, USA) at room temperature for 30 min, in accordance with the manufacturer\'s instructions (Vector Laboratories Inc.). The immunoreactions were visualised using 3,3′-diaminobenzidine as the substrate and counterstaining with haematoxylin.

Statistical analysis
--------------------

Date were expressed the mean±s.d. Differences between the test groups were analysed by Student\'s *t*-test. We used Stat View (SAS Institute Inc.) statistical software. A value of *P*\<0.05 was considered statistically significant.

RESULTS
=======

Cell cycle analysis
-------------------

At 24 h after the administration of PTX or NK105 to the LLC-tumour-bearing mice, severe cell cycle arrest at the G2/M phase was observed in the tumour cells treated with the drugs as compared with that in the control (no drug treatment) ([Figure 1C](#fig1){ref-type="fig"}). There was a tendency towards the NK105-treated LLC tumour cells ([Figure 1B](#fig1){ref-type="fig"}) showing more severe arrest at the G2/M phase than the PTX-treated cells ([Figure 1A](#fig1){ref-type="fig"}).

Antitumour activity
-------------------

Decreased tumour growth rates of the LLC tumours were observed in the mice of the radiation alone, combined PTX with radiation, and combined NK105 with radiation groups. No antitumour activity was observed following treatment with either PTX or NK105 alone, because LLC is primarily a PTX-resistant tumour. Combined NK105 therapy with radiation yielded superior antitumour activity as compared to both radiation alone (*P*=0.0047) and combined PTX therapy with radiation (*P*=0.0277) on the day 9 after the treatment initiation ([Figure 2A](#fig2){ref-type="fig"}). No significant differences in body weight changes were noted among the groups tested ([Figure 2B](#fig2){ref-type="fig"}).

Lung toxicities
---------------

Histopathological examination of the lung sections of all the mice receiving radiation showed inflammatory cell infiltration, appearance of intra-alveolar macrophages, and destruction of the alveolar architecture. Major portions of the alveolar septa in the lung sections prepared from the irradiated mice showed slight thickening, although no massive structural destruction was observed ([Figure 3A](#fig3){ref-type="fig"}). On the other hand, the lung sections prepared from the control nonirradiated group showed no significant histopathological changes ([Figure 3B](#fig3){ref-type="fig"}). Ashcroft\'s fibrosis scores in the groups of mice that received radiation ranged from 0.975 to 1.426, with no significant differences among the groups. The score in the control group was nearly zero. In the groups receiving radiation, the severity of lung fibrosis differed significantly among the mice within the same groups, as did the Ashcroft\'s scores, that is, the s.d. of the Ashcroft\'s scores in the mice receiving radiation was very high ([Figure 3C](#fig3){ref-type="fig"}).

Type III collagen deposition
----------------------------

Immunohistochemical analysis of lung sections prepared from the mice receiving radiation revealed significant collagen deposition, especially in the subpleural regions, while that of lung sections prepared from the control group showed little collagen deposition. There were no significant differences among the different groups receiving radiation ([Figure 3D](#fig3){ref-type="fig"}).

DISCUSSION
==========

It is well known that PTX enhances the radiosensitivity of tumour cells by inducing cell cycle arrest at the G2/M phase, the most radiosensitive phase of the cell cycle ([Terasima and Tolmach, 1963](#bib40){ref-type="other"}; [Sinclair and Morton, 1966](#bib38){ref-type="other"}). Many reports have confirmed the radiosensitising effect of PTX in different cell lines ([Tishler *et al*, 1992](#bib41){ref-type="other"}; [Choy *et al*, 1993](#bib9){ref-type="other"}; [Lokeshwar *et al*, 1995](#bib26){ref-type="other"}; [Rodriguez *et al*, 1995](#bib34){ref-type="other"}), *in vivo* experiments ([Milas *et al*, 1994](#bib30){ref-type="other"}, [1995](#bib31){ref-type="other"}; [Cividalli *et al*, 1998](#bib11){ref-type="other"}), and in several clinical trials of combined PTX with radiation therapy according to different schedules ([Dillman *et al*, 1990](#bib12){ref-type="other"}; [Arriagada *et al*, 1991](#bib2){ref-type="other"}; [Morton *et al*, 1991](#bib32){ref-type="other"}; [Furuse *et al*, 1999](#bib17){ref-type="other"}; [Sause *et al*, 2000](#bib37){ref-type="other"}; [Chen *et al*, 2003](#bib6){ref-type="other"}). [Chen *et al* (2003)](#bib6){ref-type="other"} examined the optimal timing of PTX treatment and irradiation in relation to the cell cycle, and recommended that radiation be given at least 5 h after PTX administration, because G2/M arrest of a lung cancer cell line was shown to start at 4 h after PTX treatment and to last for 44 h.

In our experimental model to evaluate the antitumour activity, the tumours were irradiated 24 h after a single i.v. injection of PTX or NK105. No significant increase in the antitumour activity as compared with that in the control (no treatment) was observed following a single i.v. injection of either PTX or NK105 at the dose of 45 mg kg^−1^; LLC tumours are known to be primarily resistant to PTX. In fact, the IC~50~ of PTX against an LLC tumour cell line was shown to be 84.1 n[M]{.smallcaps}, which is about 10-fold higher than that of NK105 against various cancer cell lines tested in our previous work ([Hamaguchi *et al*, 2005](#bib19){ref-type="other"}). Combined NK105 therapy with radiation yielded superior antitumour activity as compared with radiation alone or combined PTX therapy with radiation. This result suggests that NK105 has a more potent radiosensitising effect than PTX. In our study, there was a tendency towards NK105-treated LLC tumour cells showing more severe arrest at the G2/M phase as compared to PTX-treated cells at 24 h after the injection of the drugs, the timing of the radiation treatment, probably because NK105 allows a higher concentration of PTX to be maintained in the tumour than conventional PTX ([Hamaguchi *et al*, 2005](#bib19){ref-type="other"}). We suppose that this is the reason why NK105 exerted more potent radiosensitising activity than PTX.

Next, we were concerned about the adverse effects of combined NK105 therapy with radiation. New micellar drugs are designed based on the idea that DDS can accumulate in the tumour selectively, while showing reduced distribution in normal tissues. We demonstrated that the incorporation of cisplatin into micelles significantly reduced the nephrotoxicity and neurotoxicity of cisplatin ([Uchino *et al*, 2005](#bib42){ref-type="other"}). However, it was also shown that micelle- incorporated cisplatin caused transient liver dysfunction because it was trapped more avidly by the RES as compared to free cisplatin, even though the PEG of the outer shell of the micelle confers the so-called stealth effect.

In this study, our examination of the lung sections of mice treated with NK105 and radiation revealed that the histopathological changes such as inflammatory cell infiltration, appearance of intra-alveolar macrophages, and destruction of the alveolar architecture were induced by thoracic radiation and not by the accumulation of NK105 in the lung. There were no significant differences in the histopathological changes observed among the mice treated by NK105 and radiation and mice treated by radiation alone or PTX with radiation. The severity of lung fibrosis did not differ significantly among the test groups either. Although some clinical trials reported an increased incidence of pneumonitis and esophagitis following combined PTX therapy with radiation ([Taghian *et al*, 2001](#bib39){ref-type="other"}; [Hanna *et al*, 2002](#bib20){ref-type="other"}; [Chen and Okunieff, 2004](#bib5){ref-type="other"}), others reported no influence on the incidence of such adverse effects ([Ellerbroek *et al*, 2003](#bib15){ref-type="other"}; [Yu *et al*, 2003](#bib44){ref-type="other"}). Several clinical trials and *in vivo* experiments have discussed the subject, however, no definitive conclusion has been arrived at ([Mason *et al*, 1995](#bib28){ref-type="other"}; Choy *et al*, 1998; [Yu *et al*, 2004](#bib45){ref-type="other"}; [Kao *et al*, 2005](#bib21){ref-type="other"}). In our study, in regard to the incidence of esophagitis, there were no significant differences in the histopathological changes observed in the esophageal sections at one week after the treatment among the test groups (data not shown).

In conclusion, we demonstrated that combined NK105 chemotherapy with radiation exerts significant antitumour activity. Furthermore, the lung toxicity of this combined treatment modality was also acceptable as compared with that observed following radiation alone or combined PTX therapy with radiation. However, further studies are necessary to determine the effectiveness of NK105 in terms of its radiosensitising effect.
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![Cell cycle analysis. Cell cycle analysis of LLC tumour cells 24 h after PTX (**A**) or NK105 administration (**B**). Untreated control cells are shown in (**C**).](95-6603311f1){#fig1}

![Antitumour activity. Changes in the LLC tumour growth rates in the mice. (**A**) Mice receiving TXL-alone (•), NK105-alone (○), combined treatment with PTX and radiation (▪), and combined treatment with NK105 and radiation (□) were administered a single i.v. injection of PTX or NK105 at the dose 45 mg kg^−1^ on day 14 after the tumour inoculation (=on day 0 after the initial treatment). After 24 h the drugs were administered, the mice in the radiation-alone (▵) and the combined-treatment groups were irradiated (arrow). Mice in the control group (×) were given no treatment. (**B**) Changes in the relative body weight. Data were derived from the same mice as those used in the present study.](95-6603311f2){#fig2}

![H&E staining of the lungs of C57BL/6J mice surviving 36 weeks after the thoracic radiation (**A**) and sham radiation (**B**). (**C**) Semiquantitative analyses to estimate the severity of pulmonary fibrosis in the mice receiving sham radiation (□), thoracic radiation alone (▪), combined PTX with radiation (![](95-6603311i1.gif){#N0x8c72d98N0x9640978}), and combined NK105 with radiation (![](95-6603311i2.gif){#N0x8c72d98N0x96409a8}). H&E- stained lung tissue sections were assessed to estimate the severity of pulmonary fibrosis by visual grading of fibrosis (Ashcroft\'s score). Collagen III staining of the irradiated lungs of mice (**D**).](95-6603311f3){#fig3}
